Baxter International (BAX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Proposal to amend the Certificate of Incorporation to reduce the minimum number of directors from nine to seven and eliminate the maximum number, with the exact number to be set by the Board.
Board adopted a Bylaws Amendment to fix Board size within a range of seven to twelve members, effective only if the Charter Amendment is approved.
Amendments aim to provide flexibility for Board size adjustments and support ongoing Board refreshment and succession planning.
Clear parameters for Board size changes are established, with future changes to be moved to the Charter upon next amendment approval.
Board recommends voting in favor of the Proposed Charter Amendment.
Board of directors and corporate governance
Framework preserves Board's ability to adjust its size as needed for effective decision making.
Intended to ensure an optimal mix of skills, perspectives, and experiences on the Board.
Bylaws Amendment maintains disciplined parameters for Board size, consistent with governance best practices.
Shareholder rights and capital structure
Stockholders retain assurance that Board size changes will occur within clearly defined and disciplined parameters.
Stockholders can change their vote if they have already voted against the Proposed Charter Amendment.
Latest events from Baxter International
- Strategic transformation, innovation, and new launches drive growth and margin expansion.BAX
Raymond James 46th Annual Institutional Investors Conference9 Jul 2026 - Exceeded 2024 guidance, completed major divestiture, and forecasts robust 2025 growth.BAX
Q4 20248 Jul 2026 - Q2 2025 sales and EPS rose, guidance maintained, and debt reduced amid ongoing industry risks.BAX
Q2 20258 Jul 2026 - Q3 sales up 4%, adjusted EPS beat guidance; hurricane and Kidney Care sale drive major changes.BAX
Q3 20248 Jul 2026 - Stabilization, margin expansion, and capital flexibility set the stage for renewed growth in 2025.BAX
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Transformation focuses on accountability, margin expansion, and capital allocation flexibility.BAX
Bank of America Global Healthcare Conference 202613 May 2026 - All five proposals, including director elections and governance changes, passed with strong support.BAX
AGM 20265 May 2026 - Q1 2026 sales up 3% reported, adjusted EPS down 35%, full-year outlook reiterated.BAX
Q1 202630 Apr 2026 - Q4 sales up 8% but adjusted EPS down 24%; 2026 outlook flat with margin recovery expected.BAX
Q4 202512 Apr 2026